Gan & Lee Pharmaceuticals successfully achieved localization of insulin core components
April 25, 2025
Source: drugdu
47
According to the news, on April 23, Gan & Lee Pharmaceuticals announced that the localization project of the company's core component of insulin products, the bromobutyl rubber piston of the cartridge bottle, has successfully passed the review of the National Center for Drug Evaluation (CDE) and activated the conversion to A, and can be officially used for the packaging and production of insulin products. This move marks that China's insulin industry chain has achieved independent control in the field of key materials. As the first insulin company in China to realize the localization of this key material, Gan & Lee Pharmaceuticals has injected strong momentum into improving the safety of the drug supply chain and optimizing production costs.
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Yahong Pharmaceutical’s loss in the first quarter widened to 83.53 million yuan May 1, 2025
- Fosun Pharma changes its leader! Taking over from Wu Yifang, Chen Yuqing becomes the chairman of Fosun Pharma May 1, 2025
- Tiankang Bio plans to list its animal vaccine business separately on the Beijing Stock Exchange May 1, 2025
- Kangle Guard’s operating income in 2024 fell by 50.2%, and its losses expanded to 357 million yuan May 1, 2025
- Stem cell therapy leads the transformation of Japanese medicine April 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
